Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma

Purpose: There is limited standard treatment for patients with advanced cholangiocarcinoma after refractory of chemotherapy. Apatinib is a tyrosine kinase inhibitor targeting VEGFR-2, which exhibited broad-spectrum antitumor activities in previous studies. We aim to evaluate the efficacy and safety...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Cancer
Glavni autori: Mao, Jinzhu, Yang, Xu, Lin, Jianzhen, Yang, Xiaobo, Wang, Dongxu, Zhang, Lei, Bai, Yi, Bian, Jin, Long, Junyu, Xie, Fucun, Huang, Hanchun, Sang, Xinting, Chen, Shuguang, Zhao, Haitao
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2021
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7847639/
https://ncbi.nlm.nih.gov/pubmed/33532001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.53482
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items